Loading
companiesCompany
Adicet Bio
Adicet makes off-the-shelf immune cell therapies from donor gamma delta T cells, a rarer type of T cell. Its lead programme is now aimed at lupus and other autoimmune diseases, with a prostate cancer candidate expected to enter the clinic in late 2026.
Overview
Adicet Bio is a clinical-stage company developing allogeneic gamma delta T-cell therapies engineered with chimeric antigen receptors. Lead product prulacabtagene leucel (prula-cel, formerly ADI-001) is an allogeneic gamma delta CAR T candidate now developed primarily in autoimmune disease (lupus nephritis, systemic lupus erythematosus, systemic sclerosis, vasculitis and rheumatoid arthritis), with a phase 1 update and pivotal trial planning under way in 2026 after FDA alignment on outpatient dosing. In oncology, ADI-212 is a preclinical candidate for metastatic castration-resistant prostate cancer with a regulatory filing planned for the third quarter of 2026 and enrolment expected in the fourth quarter. Adicet is also building an in vivo CAR T platform for haematological malignancies and solid tumours. It completed a one-for-16 reverse stock split in December 2025 and trades on Nasdaq as ACET.
Headquarters
Redwood City, CA, US
Scorecard
All companies#434of 1244 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Cell therapy · ACET
Stage
Public
Website
Phase 2CAR-T cell therapy
ADI-270 is an experimental CAR-T cell therapy from Adicet Therapeutics in phase 2 trials for renal cell carcinoma, aimed at CD70.
Notes
top- Pipeline is now led by autoimmune indications; oncology exposure is ADI-212 (prostate) and an in vivo CAR T platform. No funding round sourced.
Similar pages
- TargetCD70
Shares ADI-270, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- PersonChristof von Kalle
Shares In vivo CAR-T, CAR-T cell therapy.
- PersonHans-Peter Kiem
Shares In vivo CAR-T, Allogeneic (off-the-shelf) cell therapy.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanySana Biotechnology
Shares In vivo CAR-T, Allogeneic (off-the-shelf) cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- TechnologyGamma-delta T cell therapy
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
cancers
fronts
technologies
drugs
Phase 2CAR-T cell therapy